Mirena (Levonorgestrel)

Levonorgestrel, the active ingredient in Mirena, is a progestin presented as a 52 mg intrauterine system (IUS) for intrauterine use. It provides long‑acting hormonal contraception and is also indicated for the management of heavy menstrual bleeding in women of reproductive age.

GNH USA supplies Mirena as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring regulatory‑approved quality and consistent availability for global health programmes. Our distribution network covers Europe, Asia, Africa and the Americas, with dedicated technical support for product handling and training.

Mirena (levonorgestrel intrauterine system) acts within the hormonal contraceptive pathway to provide targeted uterine therapy.

Contraception: offers highly effective reversible birth control for up to five years. Heavy menstrual bleeding: reduces menstrual blood loss and can improve anemia associated with menorrhagia. Endometrial hyperplasia (non‑atypical): provides progestogenic effect that helps reverse benign endometrial overgrowth.

Common Side Effects: - Irregular bleeding or spotting, especially in the first months. - Amenorrhea (absence of periods) after prolonged use. - Cramping or pelvic pain during insertion and early use. - Breast tenderness or mild hormonal acne.

Serious or Rare Side Effects: - Uterine perforation during insertion. - Expulsion of the device from the uterine cavity. - Pelvic inflammatory disease or severe infection. - Ectopic pregnancy if conception occurs. - Severe allergic reaction (anaphylaxis).

Before insertion, assess uterine position and rule out pregnancy. Screen for active pelvic infection or untreated sexually transmitted disease. Counsel patients about possible changes in bleeding patterns. Review contraindications such as current pregnancy, uterine anomalies, or breast cancer. Monitor for signs of infection, perforation, or device displacement. Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) – may reduce levonorgestrel efficacy. - Concurrent systemic hormonal therapies – may increase risk of hormonal side effects.

Moderate Interactions (Monitor Closely): - Moderate enzyme inducers (e.g., topiramate, efavirenz) – may modestly lower effectiveness. - Antifungal agents such as ketoconazole – could increase levonorgestrel levels. - Herbal supplements like St. John's wort – may decrease contraceptive reliability.